国金证券03月31日发布研报称,给予诺诚健华(688428.SH,最新价:18.99元)买入评级。评级理由主要包括:1)血液瘤领先地位稳固,多项里程碑有望年内达成;2)自免研发加速,实体瘤ADC平台蓄势待发。风险提示:竞争加剧风险、临床试验结果不及预期风险、临床时间及资金成本超预期风险、BD不及预期风险、上市进度不及预期风险。文章来源:每日经济新闻原标题:国金证券给予诺诚健华买入评级,血液瘤及自免...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.